170 related articles for article (PubMed ID: 28219799)
1. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
Simiele M; Ariaudo A; De Nicolò A; Favata F; Ferrante M; Carcieri C; Bonora S; Di Perri G; De Avolio A
J Pharm Biomed Anal; 2017 May; 138():223-230. PubMed ID: 28219799
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.
Bollen PDJ; de Graaff-Teulen MJA; Schalkwijk S; van Erp NP; Burger DM
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():76-84. PubMed ID: 30572204
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
Prathipati PK; Mandal S; Destache CJ
J Pharm Biomed Anal; 2016 Sep; 129():473-481. PubMed ID: 27497648
[TBL] [Abstract][Full Text] [Related]
4. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.
Penchala SD; Fawcett S; Else L; Egan D; Amara A; Elliot E; Challenger E; Back D; Boffito M; Khoo S
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():174-80. PubMed ID: 27290668
[TBL] [Abstract][Full Text] [Related]
5. A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Aouri M; Calmy A; Hirschel B; Telenti A; Buclin T; Cavassini M; Rauch A; Decosterd LA
J Mass Spectrom; 2013 May; 48(5):616-25. PubMed ID: 23674286
[TBL] [Abstract][Full Text] [Related]
6. UPLC-MS/MS method for the simultaneous quantification of bictegravir and 13 others antiretroviral drugs plus cobicistat and ritonavir boosters in human plasma.
Gouget H; Noé G; Barrail-Tran A; Furlan V
J Pharm Biomed Anal; 2020 Mar; 181():113057. PubMed ID: 31962247
[TBL] [Abstract][Full Text] [Related]
7. High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.
Tsuchiya K; Ohuchi M; Yamane N; Aikawa H; Gatanaga H; Oka S; Hamada A
Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28762239
[TBL] [Abstract][Full Text] [Related]
8. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.
Bennetto-Hood C; Tabolt G; Savina P; Acosta EP
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():225-32. PubMed ID: 24361860
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Courlet P; Alves Saldanha S; Cavassini M; Marzolini C; Choong E; Csajka C; Günthard HF; André P; Buclin T; Desfontaine V; Decosterd LA
J Mass Spectrom; 2020 Jun; 55(6):e4506. PubMed ID: 32160389
[TBL] [Abstract][Full Text] [Related]
10. HPLC-MS/MS method for the simultaneous quantification of dolutegravir, elvitegravir, rilpivirine, darunavir, ritonavir, raltegravir and raltegravir-β-d-glucuronide in human plasma.
Zheng Y; Aboura R; Boujaafar S; Lui G; Hirt D; Bouazza N; Foissac F; Treluyer JM; Benaboud S; Gana I
J Pharm Biomed Anal; 2020 Apr; 182():113119. PubMed ID: 32004775
[TBL] [Abstract][Full Text] [Related]
11. Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Djerada Z; Feliu C; Tournois C; Vautier D; Binet L; Robinet A; Marty H; Gozalo C; Lamiable D; Millart H
J Pharm Biomed Anal; 2013 Dec; 86():100-11. PubMed ID: 23995753
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous quantification of five antiretrovirals in human tissues using ultra-high performance liquid chromatography-tandem mass spectrometry methods for therapeutic drug monitoring at the sites of action.
West RE; Oberly PJ; Saylor AJ; Riddler SA; Nolin TD; Devanathan AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jul; 1241():124164. PubMed ID: 38823149
[TBL] [Abstract][Full Text] [Related]
13. HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues.
Ramöller IK; Abbate MTA; Vora LK; Hutton ARJ; Peng K; Volpe-Zanutto F; Tekko IA; Moffatt K; Paredes AJ; McCarthy HO; Donnelly RF
J Pharm Biomed Anal; 2022 May; 213():114698. PubMed ID: 35259714
[TBL] [Abstract][Full Text] [Related]
14. Development, validation and clinical implementation of a UPLC-MS/MS bioanalytical method for simultaneous quantification of cabotegravir and rilpivirine E-isomer in human plasma.
Bevers LAH; van Ewijk-Beneken Kolmer EWJ; Te Brake HML; Burger DM
J Pharm Biomed Anal; 2024 Jan; 238():115832. PubMed ID: 37976991
[TBL] [Abstract][Full Text] [Related]
15. A liquid chromatography-tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma.
Grégoire M; Deslandes G; Renaud C; Bouquié R; Allavena C; Raffi F; Jolliet P; Dailly E
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Nov; 971():1-9. PubMed ID: 25261833
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of an HPLC-UV method for quantification of elvitegravir and two other new antiretrovirals, dolutegravir and rilpivirine, in the plasma of HIV-positive patients.
Tempestilli M; Ammassari A; D'Avolio A; Cicalini S; Gallo AL; Fazio S; Antinori A; Pucillo LP
Biomed Chromatogr; 2018 May; ():e4274. PubMed ID: 29726595
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
Rimawi BH; Johnson E; Rajakumar A; Tao S; Jiang Y; Gillespie S; Schinazi RF; Mirochnick M; Badell ML; Chakraborty R
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348149
[TBL] [Abstract][Full Text] [Related]
18. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
Notari S; Tempestilli M; Fabbri G; Libertone R; Antinori A; Ammassari A; Agrati C
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():183-190. PubMed ID: 29276983
[TBL] [Abstract][Full Text] [Related]
19. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.
Huang J; Gautam N; Bathena SP; Roy U; McMillan J; Gendelman HE; Alnouti Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2332-8. PubMed ID: 21752731
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method to quantify antiretroviral drug concentrations in human plasma for therapeutic monitoring.
West RE; Oberly PJ; Riddler SA; Nolin TD; Devanathan AS
J Pharm Biomed Anal; 2024 Mar; 240():115932. PubMed ID: 38198884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
